Arian Lundberg

Has grant

Assistant Professor at KTH Royal Institute of Technology

KTH Royal Institute of Technology
Country flagSweden

Research Interests

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Explore related searches

Recent Grants

Grant: Open

Prostate Cancer Foundation Young Investigator Award

Open Date: 2024-11-01

Close Date: 2027-11-01

Grant: Close

Prostate Cancer Program Research Pilot Grant

Open Date: 2022-06-01

Close Date: 2023-06-01

Positions (2)

Publisher
source

Arian Lundberg

University Name
.

KTH Royal Institute of Technology

KTH Royal Institute of Technology is recruiting a doctoral student for a project in multiomics, machine learning, and cancer bioinformatics at KTH/SciLifeLab in Stockholm. The project sits within the third-cycle subject Bio Biotechnology – Cancer Bioinformatics and focuses on precision medicine, cancer progression, and the tumor microenvironment, with an emphasis on genitourinary cancers. The research will combine bioinformatics-driven analyses, multi-omics data integration, and machine learning methods to investigate factors contributing to tumor progression and their links to cancer progression. The work is especially relevant for candidates interested in cancer biology, computational biology, translational research, and data-intensive biomedical discovery. Collaboration with clinical and translational researchers may be part of the project. Supervision is proposed by Assist Prof. Arian Lundberg and Prof. Cecilia Williams . The successful candidate will join an active research environment at KTH/SciLifeLab in Stockholm and will work in a setting that values independent research, teamwork, and scientific communication. Eligibility requires a second-cycle degree or equivalent qualification according to Swedish doctoral admission rules. A master’s degree in bioinformatics, computational biology, or a related field is required, together with a strong background in cancer biology. Practical skills in Bash, R, and/or Python are essential for analysis and multiomics integration. Candidates must also have strong English communication skills and an English level equivalent to English B/6 . Two academic or research references are required, including one from a previous supervisor. Selection will prioritize candidates who can work independently, collaborate effectively, analyze complex issues, show initiative, and manage multiple tasks. Experience with machine learning, multiomics integration, interdisciplinary research, clinical or patient data, HPC, and bioinformatics pipelines is advantageous. The position is a temporary full-time doctoral appointment with salary according to KTH’s doctoral student salary agreement. Applications must be submitted through KTH’s recruitment system by 2026-09-12 . Required documents include diplomas and transcripts, evidence of language qualifications, a CV, an application letter describing research interests and future goals, and representative publications or technical reports.

2 months ago

Publisher
source

Arian Lundberg

University Name
.

KTH Royal Institute of Technology

A joint postdoctoral position is available at KTH Royal Institute of Technology and SciLifeLab in Stockholm, Sweden, in collaboration with Golnaz Taheri’s lab. This opportunity is funded by Digital Futures and focuses on the intersection of artificial intelligence, digital health, and cancer research. The research groups involved bring together expertise in AI and machine learning development, medical bioinformatics, biomarker discovery, cancer precision medicine, and clinical translation. The shared goal is to develop innovative tools that can make a real difference for patients, particularly in the field of precision medicine and diagnostics. The position is ideal for candidates with a strong background in computer science, bioinformatics, medical science, or related disciplines, and who are interested in applying AI and machine learning to solve challenges in cancer research and digital health. The collaborative environment at KTH and SciLifeLab offers access to cutting-edge resources and a vibrant research community. The position is fully funded by Digital Futures, though specific details about the stipend or salary are not provided in the announcement. Applicants should have a PhD in a relevant field and demonstrate experience in AI, machine learning, digital health, cancer research, or precision medicine. Strong research skills and the ability to work collaboratively across disciplines are highly valued. The application deadline is February 9th, 2026. Interested candidates are encouraged to review the official LinkedIn announcement for further details and to prepare their application materials accordingly.

9 months ago

Articles (18)

Year:

2026

Year:

2026

Hierarchical clustering analyses of benign, localized, and mCRPC tumors representing the expression of neuroendocrine marker genes (NE), androgen-related genes (AR), and genes related to squamous (SQUAM) differentiation

Year:

2025

Purpose: Although numerous biology-driven subtypes have been described previously in metastatic castration-resistant prostate cancer (mCRPC), unsupervised molecular subtyping based on gene expression has been less studied, especially using large cohorts. Thus, we sought to identify the intrinsic molecular subtypes of mCRPC and assess molecular and clinical correlates in the largest combined cohort of mCRPC samples with gene expression data available to date. Experimental Design: We combined and batch-effect corrected gene expression data from four mCRPC cohorts from the Fred Hutchinson Cancer Research Center ( N = 157), a small-cell neuroendocrine (NE) prostate cancer (SCNC)–enriched cohort from Weill Cornell Medicine ( N = 49), and cohorts from the Stand Up 2 Cancer/Prostate Cancer Foundation East Coast Dream Team ( N = 266) and the West Coast Dream Team ( N = 162). Results: Hierarchical clustering of RNA-sequencing data from these 634 mCRPC samples identified two distinct adenocarcinoma subtypes, one of which (adeno-immune) was characterized by higher gene expression of immune pathways, higher CIBERSORTx immune scores, diminished ASI benefit, and non–lymph node metastasis tropism compared with an adeno-classic subtype. We also identified two distinct subtypes with enrichment for an NE phenotype, including an NE-liver subgroup characterized by liver metastasis tropism, PTEN loss, and APC and SPOP mutations compared with an NE-classic subgroup. Conclusions: Our results emphasize the heterogeneity of mCRPC beyond currently accepted molecular phenotypes, and suggest that future studies should consider incorporating transcriptome-wide profiling to better understand how these differences impact treatment responses and outcomes.

Year:

2025

Supplemental Table 1: Median, Inter-Quartile Range (IQR), and 25th and 75th percentiles for Figure 2. Supplemental Table 2: Median, Inter-Quartile Range (IQR), and 25th and 75th percentiles for Figure 3. Supplemental Table 3: Proportions for Figure 4. Supplemental Table 4: Proportions for Figure 5.

Year:

2025

At high doses, alkylating drugs' toxicity leads to testicular atrophy and spermatogonial stem cells depletion, rendering survivors of childhood cancers infertile, as a recognized late effect. We used in-vivo experimental models to identify early gonadotoxic effects induced by cyclophosphamide (CPA) on prepubertal testes and to investigate if a treatment with antioxidants could reduce that toxicity. Effects were estimated by histological evaluation and whole-transcriptome RNA-sequencing (RNA-seq) of sacrificed animals at 8 hours intervals. Sixty pre-pubertal mice were randomly assigned to 1) intraperitoneal treatment with 100 mg/Kg CPA; 2) CPA in addition to antioxidants (AO) L-Carnitine (LC 50mg/kg) and N-acetyl cysteine (NAC 50); 3) AO alone; 4) control receiving saline solution (Ctrl) (N=15 for each group). Three additional animals were used for baseline assessments. On histology, changes were evident at 32 hours post-treatment. However, RNA-seq analyses revealed that the molecular impact of CPA occurred early within the first 16 hours of exposure to the drug, and that protective effects of AO in combined CPA therapy (CPA+AO) could be achieved during that period. This study demonstrates side effects of CPA on testicular tissue in the first 48 hours on transcriptional scale. Our findings indicate that early administration of AO can mitigate CPA-induced testicular damage in-vivo and suggest that protective treatments against prepubertal testis damage could be developed. However, such protective treatment should not interfere with the desired cytotoxic effects on the malignancies, thus further research is needed to evaluate the timing and how safe administration of the protectant could be achieved for medical treatment.

Year:

2025

Supplementary Figure 6 shows clinical data analysis of neoadjuvant androgen axis inhibition in primary prostate cancer as well as expression analysis of AR, MHCI, and IFNG activity in mHSPC clinical samples.

Year:

2025

Year:

2025

Supplementary Figure 6 shows clinical data analysis of neoadjuvant androgen axis inhibition in primary prostate cancer as well as expression analysis of AR, MHCI, and IFNG activity in mHSPC clinical samples.

Year:

2025

Year:

2025

Year:

2025

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Collaborators (34)

Kenny A. Rodriguez-Wallberg

Karolinska Institutet

SWEDEN
View details

Thomas O'Loughlin

Icahn School of Medicine at Mount Sinai

UNITED STATES
View details

Meng Zhang

Assistant Professor of Urology

Emory University

UNITED STATES
View details

Davide Ruggero

Professor

University of California

UNITED STATES
View details

Alec Paschalis

Institute of Cancer Research

UNITED KINGDOM
View details

David A. Quigley

Assistant Professor

University of California, San Francisco

UNITED STATES
View details

Joshua Lang

Professor

University of Wisconsin-Madison

UNITED STATES
View details

Wilbert Zwart

Senior Groupleader / professor

Eindhoven University of Technology

NETHERLANDS
View details

Luke Gilbert

Assistant Professor

University of California, San Francisco

UNITED STATES
View details

Alan Ashworth

University of California, San Francisco

UNITED STATES
View details

Zheng Xia

Associate Professor

University of Texas at Austin

UNITED STATES
View details

Alexander W. Wyatt

Assistant Professor

The University of British Columbia

CANADA
View details

Matthew Rettig

Professor

University of California, Los Angeles

UNITED STATES
View details

Adam Sharp

Team Leader

Institute of Cancer Research

UNITED KINGDOM
View details

Shuang G. Zhao

University of Wisconsin-Madison

UNITED STATES
View details

Li Zhang

Professor

UCSF

UNITED STATES
View details

Kim Chi

Chief Medical Officer

BC Cancer

CANADA
View details

Adam Sowalsky

Senior Investigator

National Cancer Institute

UNITED STATES
View details

Amir Hesam Eskafi Noghani

Karolinska Institutet

SWEDEN
View details

Michelle Badura

Lecturer

Santa Clara University

UNITED STATES
View details

Duygu Kuzuoglu Ozturk

Assistant Prof

Sabancı University

TURKEY
View details

Johann S de Bono

Head of Clinical Studies Division

Institute of Cancer Research

UNITED KINGDOM
View details

Raunak Shrestha

Assistant Professor

Uniformed Services University of the Health Sciences

UNITED STATES
View details

Tomasz Michal Beer

Oregon Health & Science University

UNITED STATES
View details

Eric J. Small

University of California, San Francisco

UNITED STATES
View details

Lawrence Fong

Fred Hutch Cancer Center

UNITED STATES
View details

Owen Witte

University Professor

University of California, Los Angeles

UNITED STATES
View details

Matthew R. Cooperberg

University of California

UNITED STATES
View details

Jonathan Chou

Assistant Professor

University of California, San Francisco

UNITED STATES
View details

Felix Y. Feng

University of California

UNITED STATES
View details

Christopher Evans

Professor

University of California, Davis

UNITED STATES
View details

Mathieu Lupien

Senior Scientist

University Health Network

CANADA
View details

Rahul Aggarwal

University of California

UNITED STATES
View details

Jessica Hawley

Assistant Professor

University of Washington

UNITED STATES
View details